An interventional study of Intermittent hypoxia and Normoxia in Intermittent Hypoxia and Healthy Volunteers, sponsored by Poitiers University Hospital. Recruiting at 1 site in France. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by Poitiers University Hospital · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 72 studies in Hypoxia with a site in France — 17 open to participants now, 17 under way, 1 of them phase 3. Hypoxia · France.
Among the 72 studies in Hypoxia with a site in France, this one is the 26th largest by planned enrollment of the 51 interventional ones that give a count, is one of 5 that started in 2026, is one of 37 with no phase, reaches primary completion later than 11 of the 16 other live ones, and was the 67th registered.
1,081 studies on the registry are indexed under Hypoxia; 213 are open to participants now.
Browse Hypoxia studies →17 of the 72 studies in Hypoxia with a site in France are open now. Recruiting first, the newest first:
University Hospital, Grenoble · Sites in France
Ages 18–55 · Healthy volunteers
Universite du Littoral Cote d'Opale · Sites in France
Ages 18–65 · Healthy volunteers
University Hospital, Strasbourg, France · Sites in France
Ages 0 days–1 days
Poitiers University Hospital · Sites in France
Ages 18–75 · Healthy volunteers
University Hospital, Montpellier · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 124 Hypoxia studies recruiting now, 52 (42%) set no upper age limit and 46 (37%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
72 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 5 · Phase 3 3 · Phase 4 5
First in 1963; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 45 across 771 interventional studies indexed under Hypoxia.
Median enrollment 40 across the 51 interventional studies, 101 across the 21 observational. Of the 39 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 72 have an industry lead sponsor. The 10 most frequent:
Poitiers University Hospital is the lead sponsor of 315 studies on the registry; 63 are open to participants now.
Poitiers University Hospital has 4 studies filed under Hypoxia — fewer than ten, so there is no comparison to draw.
4 of the studies in Hypoxia with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07516028Universite du Littoral Cote d'OpaleBrain Connectivity and Corticospinal Excitability in Response to Moderate Hypoxia | 2026-12-20 |
| NCT07585227Direction Centrale du Service de Santé des ArméesStudy of the Effects of Acute Exposure to Moderate Altitude Hypoxia on Prospective Memory. | 2026-12-31 |
| NCT05525312University Hospital, MontpellierComparison of Two Strategies of One-lung Ventilation in Patients Undergoing Carcinological Lung Resection Surgery. | 2027-03-20 |
| NCT07072975Centre Hospitalier Universitaire, AmiensCPOD Patient's Tolerance of Intermittent Exercise With Inter-exercise Recovery Under Normoxic Hypoxia | 2027-07 |
Add all 4 to your calendar (.ics) → With an account.
Among the 72 studies in Hypoxia with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Sleep apnoea-hypopnoea syndrome (SAHOS), which causes numerous comorbidities, particularly cardiovascular ones, is widespread worldwide today and incurs significant healthcare costs.
Current research in this field focuses on identifying different phenotypes in affected patients in order to provide more personalised treatment.
One of these phenotypes appears to be linked to instability in ventilatory control due to an increase in loop gain (LG) in these subjects.
However, the pathophysiology of this ventilatory control instability due to increased LG is not fully understood. It is still difficult to determine whether subjects have an intrinsically high LG or if exposure to intermittent hypoxia during OSA promotes an increase in LG.
It has also been demonstrated that OSA causes vascular hyperreactivity by increasing oxidative stress through elevated ROS production. This leads to endothelial dysfunction in response to intermittent hypoxia associated with apnoea. Extracellular vesicles (microvesicles and exosomes) have been shown to play a role in this endothelial response. These extracellular vesicles are essential for intercellular communication in both physiological and pathological situations, such as SAHOS.
Therefore, the objective of this research is to determine whether exposure to intermittent hypoxia and changes in microvesicle phenotype could influence LG, which could lead to new therapeutic advances in the context of SAHOS.
The criteria were revised on the registry on Oct 28, 2026. See what changed
Inclusion Criteria:
Non-inclusion Criteria:
Post-inclusion exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
T1 : Conduct the experiment in ambient air (without hypoxia) for six hours. T2 : Then, after a washout period of at least seven days, conduct the experiment in intermittent hypoxia via the hypoxia chamber for six hours.
Procedure: Intermittent hypoxia · Procedure: Normoxia
T1 : Conduct an experiment involving intermittent hypoxia in the hypoxia chamber for six hours. T2 : Then, after a washout period of at least seven days, conduct an experiment involving ambient air (without hypoxia).
Procedure: Intermittent hypoxia · Procedure: Normoxia
The volunteer will remain at rest in the hypoxic chamber, experiencing intermittent hypoxic conditions cyclically every 6 minutes. During one third of the cycle, they will be exposed to hypoxia in order to reduce SpO₂ to between 85% and 90%. Then, during two thirds of the cycle, they will receive oxygenation at a rate of 1 L/min (with possible subject-dependent modulations), with the aim of achieving an SpO₂ of greater than 95%. To make the hypoxia intermittent, the volunteer will also be given a medium-concentration oxygen mask that provides intermittent airflow, controlled by the D-6341 mass flow controller.
The participant will remain at rest in the hypoxic chamber under normoxic conditions. To prevent the volunteer from becoming aware of the conditions to which they are exposed, an air flow rate of 1 L/min will be used to simulate intermittent oxygenation.
The change in Loop Gain before and after 6 hours of experimental condition (intermittent hypoxia or ambient air).
Loop gain is the product of 'controller gain' (ventilatory responsiveness to CO₂ above eupnoea) and 'plant gain' (the ventilatory increase required for a given reduction in PaCO₂). The following ventilatory parameters will be measured using a gas exchange measuring device to calculate loop gain, plant gain and controller gain: PETCO₂ (in mmHg), PETO₂ (in mmHg) and Minute ventilation (VE) measured in mL/min (tidal volume x respiratory rate). For each experimental condition (test-hypoxia or control-ambient air), loop gain will be measured before the experimental condition (after 30 minutes of rest) and after the experimental condition (20 minutes before leaving the hypoxic chamber). The change in loop gain is defined as the difference between the average values (over 5 minutes) of the loop gain before and after the experimentation.
Time frame: 6 hours of experimental condition
The change in controller gain before and after 6 hours of experimental condition (intermittent hypoxia or ambient air)
The following ventilatory parameters will be measured using a gas exchange measuring device to calculate loop gain, plant gain and controller gain: PETCO₂ (in mmHg), PETO₂ (in mmHg) and Minute ventilation (VE) measured in mL/min (tidal volume x respiratory rate). For each experimental condition (test-hypoxia or control-ambient air), controller gain will be assessed before the experimental condition (after 30 minutes of rest) and after the experimental condition (20 minutes before leaving the hypoxic chamber). The change in controller gain is defined as the difference between the average values (over 5 minutes) of the controller gain before and after experimental condition.
Time frame: 6 hours of experimental condition
The change in plant gain before and after 6 hours of experimental condition (intermittent hypoxia or ambient air)
The following ventilatory parameters will be measured using a gas exchange measuring device to calculate loop gain, plant gain and controller gain: PETCO₂ (in mmHg), PETO₂ (in mmHg) and Minute ventilation (VE) measured in mL/min (tidal volume x respiratory rate). For each experimental condition (test-hypoxia or control-ambient air), plant gain will be assessed before the experimental condition (after 30 minutes of rest) and after the experimental condition (20 minutes before leaving the hypoxic chamber). The change in plant gain is defined as the difference between the average values (over 5 minutes) of the plant gain before and after experimental condition.
Time frame: 6 hours of experimental condition
The change in the quantity of extracellular vesicles before and after 6 hours of experimental condition (intermittent hypoxia versus ambient air)
The quantity of extracellular vesicles is assessed from blood samples using flow cytometry with specific antibodies. Blood samples are collected before the experimental condition (after 30 minutes of rest) and after the experimental condition (after leaving the hypoxic chamber). This change is expressed as the difference in the following extracellular vesicle concentrations before and after experimental conditioning: * EVs from platelets expressing CD41 * EVs from erythrocytes expressing CD235a * EVs from leukocytes expressing CD45 * EVs from endothelial cells expressing CD146 * EVs from granulocytes expressing CD66b and CD11b * EVs from activated leukocytes expressing CD62L * EVs from activated endothelial cells expressing CD62E * EVs from activated platelets expressing CD62P * CD62P/platelet ratio * EVs carrying the PSGL-1 ligand expressing CD162 * EVs carrying phosphatidylserine expressing annexin V
Time frame: 6 hours of experimental condition
Correlation between the change in quantity of extracellular vesicles and change in loop gain
The change in the quantity of extracellular vesicles is defined as the difference of the extracellular vesicle concentration before and after the experimental condition (intermittent hypoxia and ambient air). The change in loop gain is defined as the difference of the loop gain values before and after the experimental condition (same definition as the primary outcome). We are interested in the following extracellular vesicles: CD41, CD235a, CD45, CD146, CD66b, CD11b, CD62L, CD62E, CD62P and CD62/platelet annexin V.
Time frame: 6 hours of experimental condition
Change in loop gain before and after experimental condition (intermittent hypoxia or ambient air), in the subgroup of patients with hyperventilation syndrome and in the subgroup of patients without hyperventilation syndrome.
The change in loop gain is defined in the same way as the primary endpoint, i.e. as the difference between the measurements taken before and after the experimental condition. Hyperventilation syndrome is defined as a Nijmegen score of 23 or above at the inclusion visit.
Time frame: 6 hours of experimental condition
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Start is estimated for Oct 2026; primary completion for Dec 2027, 14 months later.
Of 324 non-industry interventional studies with no phase under Hypoxia, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 27. This study's planned 14 months is above that.
Counting every sponsor, half of 354 studies reached it within 12 months; a quarter within 3 and three quarters within 27.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: start Jul 2026 → Oct 2026, primary completion Sep 2027 → Dec 2027 and completion Sep 2027 → Dec 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Poitiers University Hospital →